Genetically modified T cells for treating malignant tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the safety, tolerability, and initial effectiveness of CAR-T cell therapy in patients with various malignant tumors, including lung, gastric, colorectal, and breast cancers. Participants will undergo CAR-T cell reinfusion, and the study will monitor progression-free survival, overall survival, disease control rate, clinical benefit rate, and quality of life. Additionally, the research will explore changes in T cell receptor diversity, lymphocyte subsets, immune cell function, and serum cytokine levels following treatment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Subjects with malignant tumors confirmed by histopathology or cytology, including: non-small cell lung cancer, esophageal squamous cell carcinoma, gastric cancer, colorectal cancer, liver cancer, pancreatic cancer, kidney cancer, cervical squamous cell carcinoma, ovarian cancer, breast cancer, melanoma, and brain glia tumor, lymphoma, etc.;
2. Age: 18 \~ 75 years old; Gender: no limitation;
3. Have sufficient hematopoietic capacity: ANC \>1500 cells /mm3, Blood plate count \>50,000 cells /mm3, HGB \>9.0g/dL, ALC \>9 cells /mm3;
4. Adequate liver and kidney function: AST and ALT ≤2.5 ULN in patients without liver metastasis and ≤5 times in patients with liver metastasis. ULN; Bilirubin ≤1.5 ULN (excluding hyperbilirubinemia or hyperbilirubin of non-hepatic origin); Creatinine ≤2.0 ULN. Creatinine clearance and creatinine clearance hormone ≥40 mL/min;
5. PT/INR \<1.5 ULN, and PTT/αPTT \<1.5 ULN;
6. For desirable tumor tissues or tissue white tablets, positive expression of at least one of Mesothelin, NKG2D, HER2, CD276, CD19, BCMA and other antigens can be selected for clinical trials;
7. ECOG physical status score 0 \~ 2 points;
8. Expected survival \>6 months;
9. Subject accepts voluntarily

Exclusion Criteria:

1. Received anti-PD1, anti-PD-L1 or anti-PD-L2 antibody therapy or other immunotherapy methods one month before treatment with immune cells in this study;
2. History of organ transplantation;
3. Pregnancy or lactation;
4. Positive for high baseline HBV DNA levels (≥2000 IU/ml), HIV antibodies (anti-HIV), hepatitis C virus antibodies (anti-HCV), or treponema pallidum antibodies;
5. There is active infection;
6. There are active brain metastases (except asymptomatic or stable brain metastases after treatment);
7. Combined with a second tumor; With the exception of patients with basal cell carcinoma of the skin, superficial bladder cancer, squamous cell carcinoma of the skin, cervical carcinoma in situ, or papillary thyroid cancer who achieved complete response to the second tumor for more than 5 years and did not require treatment during the study period;
8. Severe autoimmune diseases such as ulcerative colitis, Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus, autoimmune vasculitis, or Wegener's granulomatosis require long-term (more than 2 months) systemic immunosuppressive therapy;
9. People with allergies;
10. NYHA heart failure grade ≥2 or hypertension can not be controlled after standard treatment, have a history of myocarditis or have a heart attack within one year;
11. Thrombotic diseases with active bleeding that require treatment;
12. Patients who are determined by the researcher to have a serious uncontrollable disease or other conditions that may affect the treatment in this study and are considered unsuitable.

Where it's running

• Zhengzhou University First Affiliated Hospital
  Zhengzhou, Henan, China Recruiting

Study contacts

• Study coordinator: Yi Zhang, MD
• Email: yizhang@zzu.edu.cn
• Phone: +86 15138928971

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• SumMET: Targeted radioligand therapy for c-MET–positive solid tumors

  This first‑in‑human study tests the safety and potential effectiveness of a radioligand therapy called [225Ac]Ac-FL-261 in adults with advanced or metastatic solid tumors that overexpress c-MET.

  Recruiting at 2 sites Phase 1/2 Full-Life Technologies UK Limited · Minneapolis, Minnesota and 1 other locations · NCT07873450

• SHR-4595 Injection in Advanced Solid Tumors: Safety, Tolerability, and Dosing in Phase 1

  This early-phase trial tests SHR-4595 injections to see if they are safe and tolerable for adults with advanced solid tumors who have exhausted standard treatments.

  Recruiting at 2 sites Phase 1 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Shenyang, Liaoning and 1 other locations · NCT07830199

• FAPI PET imaging with FAPI-RuiJ and FAPI-04 in solid tumors

  This study tests two FAP-targeted PET tracers (FAPI-RuiJ and FAPI-04) to see which better detects, stages, and monitors solid tumors.

  Recruiting Ruijin Hospital · Shanghai · NCT07776899

• Trop-2 Targeted PET/CT for Recurrent and Metastatic Thyroid Cancer

  This study tests whether a Trop-2 targeted PET/CT scan can better detect recurrent or metastatic thyroid cancer in adults than another PET/CT scan (FAPI).

  Recruiting The First Affiliated Hospital of Xiamen University · Xiamen, Fujian · NCT07753499

• SI-B036 in locally advanced or metastatic breast cancer and other solid tumors

  Scientists are testing SI-B036 to see if it is safe and tolerable in adults with advanced breast cancer or other solid tumors and to get early signals of whether it might help.

  Recruiting Phase 1 Sichuan Baili Pharmaceutical Co., Ltd. · Beijing, Beijing Municipality · NCT07753226

• Methylscape test in body fluids for multi-cancer detection in Colombia

  A simple blood, urine, or saliva test called Methylscape is being tested to see if it can detect multiple cancers and identify where the signal is coming from, using people with cancer and healthy volunteers in Colombia.

  Recruiting Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo · Bogotá, Bogota D.C. · NCT07741435

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.